The booster dose of the Pfizer/BioNTech vaccine provides an exceptionally high level of protection against the coronavirus, including the delta variant, new trial data shows.
Pfizer said its trial of 10,000 people found that the risk of symptomatic infection was reduced by 95.6 percent in people who received the third dose, compared to those who were vaccinated.
“Based on these findings, we believe that booster vaccination can play an important role in epidemic prevention and return to normalcy, in addition to broader global access to vaccines for all,” said Ugur Sahin, Head of BioNTech.
Study participants were given either a booster jab or a placebo, on average, 11 months after receiving their second dose.
Pfizer said only five cases of Covid-19 were reported in the booster cohort, compared with 109 in the placebo group.
The mean age of participants was 53 years, with 55.5 percent of participants being between 16 and 55 years old, and 23.3 percent 65 years of age or older.
The trial took place during the period when the delta version was prevalent, proving that the booster jab is effective against this form of the virus.
Pfizer and BioNTech said the vaccine’s effectiveness was “consistent” across age, gender, race, ethnicity and people with underlying health conditions. He also said that the administration of the third dose was safe.
Both companies said they would submit detailed test results to the Food and Drug Administration in the US, the European Medicines Agency and other regulatory agencies as soon as possible.
Regulators in the US, EU and UK have already authorized a third dose of COVID-19 vaccines by Pfizer/BioNtech and Moderna for patients with weakened immune systems who have been protected by the two-dose regimen. likely to happen.
Research has shown that the effectiveness of the Pfizer vaccine against symptomatic disease drops from 96 percent to 84 percent four months after the second dose.
Amid fears of reduced immunity – although the vaccine, along with other authorized jabs, continues to provide high levels of protection against hospitalization and death – many countries have already launched national booster programs for the elderly and vulnerable groups. has been carried forward.
Credit: www.independent.co.uk /